Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA approves AstraZeneca’s intravenous Nexium
Nexium IV (esomeprazole magnesium) is now approved as an intravenous infusion or injection for the short-term treatment of gastroesophageal reflux disease (GERD) patients, with a history of erosive
Nexium IV (esomeprazole magnesium) is now approved as an intravenous infusion or injection for the short-term treatment of gastroesophageal reflux disease (GERD) patients, with a history of erosive
The filing is the first step in evaluating the potential of AMD3100, a stem cell mobilizer, to help repair damaged heart tissue in patients who have suffered heart
This drug candidate, an antagonist of the Hedgehog signaling pathway, is being developed to treat basal cell carcinoma, the most common form of all human cancers. It was
The FDA approved Zyflo in 1996 for the prevention and chronic treatment of asthma in patients 12 years of age and older. Critical Therapeutics in-licensed worldwide rights to
Under the agreement, Technology Partnerships Canada (TPC) will invest up to $9.3 million in the Migenix’ R&D activities related to MX-2401, a novel lipopeptide candidate in preclinical development
Upon publication of the final rule, Sepracor will commence full-scale commercial launch of Lunesta (eszopiclone). The company expects Lunesta to be widely available by prescription in pharmacies within
The study evaluated the effects of TQ-1015 in inflammatory pain against mechanical allodynia and thermal hyperalgesia and compared its potency with morphine. The results were presented at the
The first agreement between the companies was announced in November 2002 and focused on drug targets for immunological diseases. This new agreement expands the collaboration scope and will
The new vaccine, named MOPV1, will be used first in Egypt as a critical part of a new World Health Organization (WHO) strategy to end polio transmission by
Asmanex Twisthaler 220mcg (mometasone furoate inhalation powder) is now approved for the first-line maintenance treatment of asthma as preventive therapy in patients 12 years of age and older.